Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

@article{Staels2013HepatoprotectiveEO,
  title={Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.},
  author={Bart Staels and Anne Rubenstrunk and Benoit Noel and G{\'e}raldine Rigou and Philippe Delataille and Lesley J Millatt and Morgane Baron and Anthony Lucas and Anne Tailleux and Dean W. Hum and Vlad Ratziu and Bertrand Cariou and R{\'e}my Hanf},
  journal={Hepatology},
  year={2013},
  volume={58 6},
  pages={1941-52}
}
UNLABELLED Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no pharmacological treatment is approved for NAFLD/NASH. Here, we report on preclinical and clinical data with GFT505, a novel dual peroxisome proliferator-activated receptor alpha/delta (PPAR-α/δ) agonist. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
84 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis

  • LB VanWagner, ME Rinella
  • Therap Adv Gastroenterol
  • 2011
Highly Influential
9 Excerpts

The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high HEPATOLOGY

  • E Barroso, R Rodriguez-Calvo, +4 authors M. Vazquez-Carrera
  • STAELS ET AL
  • 2013
1 Excerpt

Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis

  • CZ Larter, MM Yeh, DM Van Rooyen, J Brooling, K Ghatora, GC. Farrell
  • J Gastroenterol Hepatol 2012;27:341-350
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…